AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 NOV 4 - (NewsRx.com & NewsRx.net) -- Tamoxifen alters cytokines and nitric oxide levels in breast cancer patients.
According to published research from Turkey, "vascular endothelial growth factor (VEGF) is a multi-functional cytokine that has been suggested to be a major angiogenic factor in breast cancer. Nitric oxide (NO) is a potent biological molecule that participates in the multi-step process of carcinogenesis. Interleukin (IL)-18 has been shown to have potent anti-tumor effects."
"In this study, we investigated the effect of tamoxifen therapy on serum VEGF, NO and IL-18 activity in breast cancer patients. Serum levels of VEGF, nitrate + nitrite and IL-18 were measured in 34 postmenopausal breast cancer patients before and 3 months after the tamoxifen therapy. Both serum VEGF and IL-18 levels decreased after tamoxifen therapy (p=0.051, p
"Serum VEGF levels increased in patients with endometrial thickness, while patients without endometrial thickness had a significant reduction in serum VEGF levels after therapy (p <0.05). Serum nitrate + nitrite levels increased after the therapy, but this was not statistically significant (p>0.05). A decrease in serum VEGF levels with tamoxifen therapy may be a reflection of reduced angiogenic activity in patients without endometrial thickness.
"The negative effect of tamoxifen therapy on IL-18, which is known ...
Source: HighBeam Research, Tamoxifen alters cytokines and nitric oxide levels in breast cancer...